- Home
- SDOT vs INAB Comparison
SDOT vs INAB Comparison
Compare SDOT & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDOT
- INAB
- Stock Information
- Founded
- SDOT 2014
- INAB 2016
- Country
- SDOT United States
- INAB United States
- Employees
- SDOT N/A
- INAB N/A
- Industry
- SDOT Restaurants
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- SDOT Consumer Discretionary
- INAB Health Care
- Exchange
- SDOT Nasdaq
- INAB Nasdaq
- Market Cap
- SDOT 8.0M
- INAB 7.5M
- IPO Year
- SDOT 2020
- INAB 2021
- Fundamental
- Price
- SDOT $0.92
- INAB $2.37
- Analyst Decision
- SDOT
- INAB Strong Buy
- Analyst Count
- SDOT 0
- INAB 2
- Target Price
- SDOT N/A
- INAB $108.00
- AVG Volume (30 Days)
- SDOT 685.6K
- INAB 106.8K
- Earning Date
- SDOT 08-14-2025
- INAB 08-07-2025
- Dividend Yield
- SDOT N/A
- INAB N/A
- EPS Growth
- SDOT N/A
- INAB N/A
- EPS
- SDOT 1.07
- INAB N/A
- Revenue
- SDOT $726,598,000.00
- INAB N/A
- Revenue This Year
- SDOT $12.76
- INAB N/A
- Revenue Next Year
- SDOT $5.54
- INAB N/A
- P/E Ratio
- SDOT $0.85
- INAB N/A
- Revenue Growth
- SDOT 18.91
- INAB N/A
- 52 Week Low
- SDOT $0.84
- INAB $1.98
- 52 Week High
- SDOT $5.70
- INAB $21.21
- Technical
- Relative Strength Index (RSI)
- SDOT 39.75
- INAB 52.95
- Support Level
- SDOT $0.85
- INAB $2.20
- Resistance Level
- SDOT $0.98
- INAB $2.38
- Average True Range (ATR)
- SDOT 0.07
- INAB 0.13
- MACD
- SDOT 0.01
- INAB 0.04
- Stochastic Oscillator
- SDOT 40.54
- INAB 81.27
About SDOT Sadot Group Inc.
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.